Advanced search
Publication Cover
Pharmacogenomics and Personalized Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
326
Views
7
CrossRef citations to date
0
Altmetric
Review

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

Laura PaciniDivision of Molecular Pathology, The Institute of Cancer Research, London, UK
,
Andrew D JenksDivision of Molecular Pathology, The Institute of Cancer Research, London, UK
,
Simon VyseDivision of Molecular Pathology, The Institute of Cancer Research, London, UK
,
Christopher P WildingDivision of Molecular Pathology, The Institute of Cancer Research, London, UK
,
Amani ArthurDivision of Molecular Pathology, The Institute of Cancer Research, London, UK
&
Paul H HuangDivision of Molecular Pathology, The Institute of Cancer Research, London, UKCorrespondence[email protected]
Pages 301-317 | Published online: 09 Mar 2021

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Zhiyuan Zhou, Xiaofeng Wu, Riming Zhan, Xiangyong Li, Dazhao Cheng, Li Chen, Tianyu Wang, Hua Yu, Guihong Zhang & Xudong Tang. (2022) Exosomal epidermal growth factor receptor is involved in HPV-16 E7-induced epithelial-mesenchymal transition of non-small cell lung cancer cells: A driver of signaling in vivo. Cancer Biology & Therapy 23:1, pages 1-13.
Read now

Articles from other publishers (6)

Jiawei Xu, Yiyi Xiong, Zhou Xu, Hongquan Xing, Lingyun Zhou & Xinyi Zhang. (2022) From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Frontiers in Medicine 9.
Crossref
Tao Zhang, Fang Feng, Linjiang Tong, Shingpan Chan, Yi Chen, Yan Li, Peiran Song, Yingqiang Liu, Gang Bai, Mengzhen Lai, Yi Ning, Yanan Wang, Yan Fang, Zilu Pan, Meiyu Geng, Ke Ding, Jian Ding & Hua Xie. (2022) ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion. Frontiers in Drug Discovery 2.
Crossref
Jun Wang, Daniel Lam, Jeffrey Yang & Longqin Hu. (2022) Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. Medicinal Chemistry Research 31:10, pages 1647-1662.
Crossref
Laura Pacini, Virginia N. Cabal, Mario A. Hermsen & Paul H. Huang. (2022) EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma. Cancers 14:2, pages 394.
Crossref
Leitao Sun, Shuning Ding, Qi Luo, Peipei Wang, Xiao Yang, Linqin Wu, Yangfan Chen, Xueer Zheng, Hang Zhang, Li Yuan, Shanming Ruan & Changsheng Xie. (2021) Taxus wallichiana var. chinensis (Pilg.) Florin Aqueous Extract Suppresses the Proliferation and Metastasis in Lung Carcinoma via JAK/STAT3 Signaling Pathway. Frontiers in Pharmacology 12.
Crossref
Laurence Booth, Cameron West, Robert P. Moore, Daniel Von Hoff & Paul Dent. (2021) GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins. Frontiers in Oncology 11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.